| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endosonography | 47 | 2011 | 177 | 3.670 |
Why?
|
| Esophageal Neoplasms | 18 | 2021 | 150 | 1.530 |
Why?
|
| Lymph Nodes | 13 | 2010 | 258 | 1.210 |
Why?
|
| Adenocarcinoma | 16 | 2021 | 475 | 1.150 |
Why?
|
| Colonic Polyps | 3 | 2015 | 63 | 0.930 |
Why?
|
| Colonoscopy | 4 | 2015 | 156 | 0.850 |
Why?
|
| Capsule Endoscopy | 2 | 2012 | 10 | 0.850 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2015 | 185 | 0.840 |
Why?
|
| Biopsy, Fine-Needle | 14 | 2011 | 76 | 0.770 |
Why?
|
| Biopsy, Needle | 14 | 2004 | 191 | 0.760 |
Why?
|
| Barrett Esophagus | 5 | 2021 | 57 | 0.620 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2015 | 629 | 0.590 |
Why?
|
| Lymphatic Metastasis | 16 | 2010 | 274 | 0.590 |
Why?
|
| Lung Neoplasms | 15 | 2010 | 1173 | 0.570 |
Why?
|
| Pancreatitis | 6 | 2007 | 279 | 0.560 |
Why?
|
| Pancreatic Neoplasms | 8 | 2014 | 332 | 0.540 |
Why?
|
| Tonsillar Neoplasms | 1 | 2015 | 7 | 0.530 |
Why?
|
| Gastroscopy | 1 | 2015 | 45 | 0.520 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2015 | 2324 | 0.520 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 64 | 0.510 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2007 | 300 | 0.510 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 160 | 0.500 |
Why?
|
| Biomarkers, Tumor | 5 | 2015 | 508 | 0.430 |
Why?
|
| Mental Recall | 1 | 2013 | 72 | 0.420 |
Why?
|
| Mediastinal Diseases | 2 | 2004 | 15 | 0.410 |
Why?
|
| Inservice Training | 1 | 2012 | 68 | 0.410 |
Why?
|
| Humans | 91 | 2021 | 68618 | 0.400 |
Why?
|
| Sensitivity and Specificity | 25 | 2015 | 1753 | 0.400 |
Why?
|
| Neoplasm Staging | 21 | 2010 | 800 | 0.400 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 10 | 2002 | 348 | 0.390 |
Why?
|
| Education, Nursing | 1 | 2012 | 55 | 0.390 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2021 | 9 | 0.390 |
Why?
|
| Sarcoidosis | 2 | 2004 | 77 | 0.390 |
Why?
|
| Middle Aged | 43 | 2021 | 21147 | 0.350 |
Why?
|
| Pancreas | 5 | 2004 | 225 | 0.340 |
Why?
|
| Aged | 37 | 2021 | 14862 | 0.340 |
Why?
|
| Diagnosis, Differential | 10 | 2012 | 1140 | 0.330 |
Why?
|
| Female | 51 | 2021 | 38074 | 0.320 |
Why?
|
| Mediastinum | 8 | 2010 | 39 | 0.310 |
Why?
|
| Esophagus | 8 | 2011 | 303 | 0.310 |
Why?
|
| Stents | 6 | 1997 | 657 | 0.290 |
Why?
|
| Adult | 37 | 2015 | 21403 | 0.280 |
Why?
|
| Male | 49 | 2021 | 37321 | 0.280 |
Why?
|
| Common Bile Duct Neoplasms | 3 | 2002 | 12 | 0.270 |
Why?
|
| Ampulla of Vater | 3 | 2002 | 34 | 0.270 |
Why?
|
| Prospective Studies | 15 | 2021 | 3705 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 767 | 0.260 |
Why?
|
| Thrombophlebitis | 1 | 2005 | 47 | 0.260 |
Why?
|
| Portal Vein | 1 | 2005 | 46 | 0.260 |
Why?
|
| Esophagoscopy | 3 | 2011 | 72 | 0.260 |
Why?
|
| Colitis | 2 | 2015 | 156 | 0.250 |
Why?
|
| Esophagitis | 2 | 2015 | 45 | 0.250 |
Why?
|
| Bile Ducts | 4 | 1998 | 59 | 0.240 |
Why?
|
| Ultrasonography, Interventional | 5 | 2005 | 119 | 0.240 |
Why?
|
| Esophageal Stenosis | 2 | 2004 | 36 | 0.240 |
Why?
|
| Aged, 80 and over | 17 | 2015 | 4848 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 468 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2005 | 756 | 0.220 |
Why?
|
| Clinical Competence | 4 | 2012 | 657 | 0.220 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2021 | 40 | 0.210 |
Why?
|
| Endoscopy, Digestive System | 5 | 2015 | 78 | 0.200 |
Why?
|
| Rectal Neoplasms | 2 | 2020 | 75 | 0.200 |
Why?
|
| Gastroenteritis | 1 | 2002 | 19 | 0.200 |
Why?
|
| Cholelithiasis | 2 | 1999 | 66 | 0.200 |
Why?
|
| Azathioprine | 1 | 2001 | 16 | 0.200 |
Why?
|
| Eosinophilia | 1 | 2002 | 47 | 0.200 |
Why?
|
| Crohn Disease | 1 | 2001 | 38 | 0.190 |
Why?
|
| Colitis, Ulcerative | 1 | 2001 | 53 | 0.190 |
Why?
|
| Pilot Projects | 5 | 2013 | 1342 | 0.190 |
Why?
|
| Predictive Value of Tests | 9 | 2015 | 1465 | 0.190 |
Why?
|
| Cholangiography | 2 | 1999 | 55 | 0.190 |
Why?
|
| Retrospective Studies | 15 | 2021 | 7277 | 0.190 |
Why?
|
| Cholestasis | 3 | 2007 | 90 | 0.190 |
Why?
|
| Adenoma | 1 | 2002 | 132 | 0.180 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 63 | 0.180 |
Why?
|
| Esophageal Achalasia | 2 | 1999 | 78 | 0.180 |
Why?
|
| Video Recording | 1 | 2001 | 145 | 0.180 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 1997 | 85 | 0.170 |
Why?
|
| Observer Variation | 3 | 2012 | 330 | 0.160 |
Why?
|
| Preoperative Care | 2 | 2008 | 275 | 0.160 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1999 | 59 | 0.160 |
Why?
|
| Precision Medicine | 1 | 2020 | 111 | 0.160 |
Why?
|
| Ultrasonography | 5 | 1997 | 453 | 0.160 |
Why?
|
| Toxoplasmosis | 1 | 1997 | 13 | 0.150 |
Why?
|
| Catheter Ablation | 2 | 2011 | 229 | 0.150 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 1997 | 26 | 0.150 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 514 | 0.150 |
Why?
|
| Pancreatitis, Chronic | 2 | 2011 | 168 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2007 | 710 | 0.140 |
Why?
|
| Anti-Dyskinesia Agents | 1 | 1997 | 3 | 0.140 |
Why?
|
| Botulinum Toxins | 1 | 1997 | 18 | 0.140 |
Why?
|
| Pancreatic Ducts | 3 | 2011 | 76 | 0.140 |
Why?
|
| Histoplasmosis | 1 | 2015 | 5 | 0.130 |
Why?
|
| Melena | 1 | 2015 | 8 | 0.130 |
Why?
|
| Immunocompetence | 1 | 2015 | 19 | 0.130 |
Why?
|
| Ulcer | 1 | 2015 | 27 | 0.130 |
Why?
|
| Models, Biological | 1 | 2020 | 981 | 0.130 |
Why?
|
| Adenomatous Polyps | 1 | 2015 | 18 | 0.130 |
Why?
|
| Registries | 2 | 2004 | 733 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 5 | 2004 | 369 | 0.130 |
Why?
|
| Reproducibility of Results | 8 | 2011 | 2077 | 0.120 |
Why?
|
| Medically Uninsured | 1 | 2015 | 99 | 0.120 |
Why?
|
| Anemia | 1 | 2015 | 104 | 0.120 |
Why?
|
| Gastrostomy | 1 | 2015 | 110 | 0.120 |
Why?
|
| RNA, Messenger | 5 | 2007 | 1664 | 0.120 |
Why?
|
| Linear Models | 3 | 2013 | 521 | 0.120 |
Why?
|
| Biopsy | 2 | 2015 | 540 | 0.120 |
Why?
|
| Catheterization | 2 | 1996 | 209 | 0.120 |
Why?
|
| Herpes Simplex | 1 | 1994 | 35 | 0.120 |
Why?
|
| Poverty | 1 | 2015 | 219 | 0.120 |
Why?
|
| Herpesvirus 1, Human | 1 | 1994 | 30 | 0.120 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 30 | 0.120 |
Why?
|
| Biofilms | 1 | 1994 | 72 | 0.120 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 54 | 0.110 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 39 | 0.110 |
Why?
|
| Endoscopy | 3 | 1996 | 464 | 0.110 |
Why?
|
| South Carolina | 3 | 2015 | 2752 | 0.110 |
Why?
|
| Poisson Distribution | 1 | 2013 | 85 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 299 | 0.110 |
Why?
|
| Common Bile Duct | 1 | 1992 | 22 | 0.110 |
Why?
|
| Neoplasm Proteins | 2 | 2007 | 307 | 0.110 |
Why?
|
| Proteomics | 1 | 2015 | 246 | 0.110 |
Why?
|
| Follow-Up Studies | 6 | 2010 | 3259 | 0.100 |
Why?
|
| Precancerous Conditions | 2 | 2011 | 74 | 0.100 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 306 | 0.100 |
Why?
|
| Telephone | 1 | 2013 | 160 | 0.100 |
Why?
|
| Fluoroscopy | 2 | 1996 | 152 | 0.100 |
Why?
|
| Liver Neoplasms | 3 | 2011 | 334 | 0.100 |
Why?
|
| Family Health | 1 | 2012 | 83 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2012 | 2358 | 0.100 |
Why?
|
| Feasibility Studies | 6 | 2010 | 652 | 0.100 |
Why?
|
| Occupational Exposure | 1 | 1992 | 122 | 0.100 |
Why?
|
| Watchful Waiting | 1 | 2011 | 25 | 0.100 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2010 | 9 | 0.090 |
Why?
|
| Biliary Fistula | 1 | 1990 | 3 | 0.090 |
Why?
|
| Treatment Outcome | 6 | 2021 | 7029 | 0.090 |
Why?
|
| Image Enhancement | 1 | 2011 | 143 | 0.090 |
Why?
|
| Fluorocarbons | 1 | 2011 | 82 | 0.090 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1990 | 106 | 0.080 |
Why?
|
| Lymphatic Diseases | 2 | 2011 | 27 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2013 | 2800 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2015 | 1553 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2005 | 2223 | 0.080 |
Why?
|
| Common Bile Duct Diseases | 2 | 2002 | 24 | 0.080 |
Why?
|
| Algorithms | 3 | 2015 | 1196 | 0.080 |
Why?
|
| Liver Diseases | 1 | 1990 | 193 | 0.080 |
Why?
|
| Bronchoscopes | 1 | 2008 | 9 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2007 | 1330 | 0.070 |
Why?
|
| Contrast Media | 1 | 2011 | 595 | 0.070 |
Why?
|
| Pregnancy | 2 | 1992 | 2334 | 0.070 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2007 | 137 | 0.070 |
Why?
|
| Fluorouracil | 2 | 2020 | 130 | 0.070 |
Why?
|
| Sphincterotomy, Endoscopic | 2 | 1998 | 79 | 0.070 |
Why?
|
| Bile Duct Diseases | 2 | 1997 | 28 | 0.070 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2007 | 46 | 0.070 |
Why?
|
| United States | 3 | 2021 | 7367 | 0.070 |
Why?
|
| Colorectal Neoplasms | 2 | 2004 | 561 | 0.070 |
Why?
|
| Liver | 3 | 2002 | 1118 | 0.070 |
Why?
|
| Bronchoscopy | 3 | 2004 | 147 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2008 | 2007 | 0.060 |
Why?
|
| Abdominal Pain | 1 | 2005 | 97 | 0.060 |
Why?
|
| Adolescent | 7 | 2010 | 8912 | 0.060 |
Why?
|
| Adrenal Glands | 1 | 2004 | 46 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2007 | 753 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2005 | 1851 | 0.060 |
Why?
|
| Needles | 1 | 2004 | 34 | 0.060 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2004 | 23 | 0.060 |
Why?
|
| Stomach | 1 | 2004 | 80 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 2 | 1997 | 107 | 0.060 |
Why?
|
| Mediastinal Cyst | 1 | 2003 | 5 | 0.060 |
Why?
|
| Combined Modality Therapy | 3 | 2004 | 951 | 0.060 |
Why?
|
| Prognosis | 5 | 2010 | 2093 | 0.060 |
Why?
|
| Mediastinoscopy | 1 | 2003 | 13 | 0.060 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2007 | 85 | 0.050 |
Why?
|
| Logistic Models | 2 | 2009 | 1420 | 0.050 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 1995 | 171 | 0.050 |
Why?
|
| Telomerase | 1 | 2003 | 85 | 0.050 |
Why?
|
| Sphincter of Oddi | 1 | 2002 | 51 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 446 | 0.050 |
Why?
|
| International Cooperation | 1 | 2002 | 88 | 0.050 |
Why?
|
| Celiac Artery | 1 | 2001 | 12 | 0.050 |
Why?
|
| Palliative Care | 1 | 2004 | 271 | 0.050 |
Why?
|
| False Negative Reactions | 1 | 2001 | 63 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 2 | 2004 | 561 | 0.050 |
Why?
|
| Carcinoma, Small Cell | 1 | 2001 | 53 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2001 | 95 | 0.050 |
Why?
|
| Costs and Cost Analysis | 2 | 1999 | 193 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2001 | 47 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2002 | 239 | 0.050 |
Why?
|
| Manometry | 1 | 2002 | 276 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 306 | 0.050 |
Why?
|
| Mediastinal Neoplasms | 3 | 2008 | 27 | 0.050 |
Why?
|
| Decision Support Techniques | 2 | 2000 | 191 | 0.050 |
Why?
|
| Dyspepsia | 1 | 2000 | 8 | 0.050 |
Why?
|
| Radiography | 1 | 2002 | 572 | 0.050 |
Why?
|
| Metaplasia | 2 | 2011 | 27 | 0.050 |
Why?
|
| Transducers | 1 | 2000 | 21 | 0.040 |
Why?
|
| Acute Disease | 2 | 2002 | 658 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 238 | 0.040 |
Why?
|
| Canada | 1 | 2021 | 267 | 0.040 |
Why?
|
| Cetuximab | 1 | 2020 | 19 | 0.040 |
Why?
|
| Pancreatic Diseases | 1 | 2000 | 66 | 0.040 |
Why?
|
| Endoscopes, Gastrointestinal | 2 | 1997 | 17 | 0.040 |
Why?
|
| Organoids | 1 | 2020 | 42 | 0.040 |
Why?
|
| Lung | 3 | 2005 | 849 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 70 | 0.040 |
Why?
|
| Condoms | 1 | 2000 | 67 | 0.040 |
Why?
|
| Dilatation | 1 | 2000 | 58 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 104 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 78 | 0.040 |
Why?
|
| HLA-DQ Antigens | 1 | 1999 | 19 | 0.040 |
Why?
|
| Safety | 1 | 2000 | 145 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 1999 | 41 | 0.040 |
Why?
|
| Carcinosarcoma | 1 | 1999 | 12 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2000 | 1046 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 304 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 1026 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 1999 | 91 | 0.040 |
Why?
|
| Alleles | 1 | 1999 | 386 | 0.040 |
Why?
|
| Colonoscopes | 1 | 1998 | 2 | 0.040 |
Why?
|
| Professional Competence | 1 | 1999 | 100 | 0.040 |
Why?
|
| Toxoplasma | 1 | 1997 | 23 | 0.040 |
Why?
|
| Sigmoidoscopy | 1 | 1997 | 38 | 0.040 |
Why?
|
| Anus Neoplasms | 1 | 1998 | 37 | 0.040 |
Why?
|
| Gallstones | 1 | 1997 | 58 | 0.040 |
Why?
|
| Injections, Intralesional | 1 | 1997 | 25 | 0.040 |
Why?
|
| Cholestasis, Extrahepatic | 1 | 1996 | 14 | 0.030 |
Why?
|
| Disease Progression | 2 | 2011 | 1038 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1998 | 346 | 0.030 |
Why?
|
| Esophageal Cyst | 1 | 1996 | 1 | 0.030 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1996 | 18 | 0.030 |
Why?
|
| Histoplasma | 1 | 2015 | 4 | 0.030 |
Why?
|
| Quality of Life | 1 | 2004 | 1515 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1999 | 931 | 0.030 |
Why?
|
| Analysis of Variance | 3 | 2004 | 1040 | 0.030 |
Why?
|
| Cholecystectomy | 2 | 1993 | 79 | 0.030 |
Why?
|
| RNA, Neoplasm | 2 | 2007 | 76 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 1997 | 1174 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2015 | 174 | 0.030 |
Why?
|
| Mutation | 1 | 2020 | 1213 | 0.030 |
Why?
|
| Polyethylenes | 1 | 1994 | 31 | 0.030 |
Why?
|
| HIV Seronegativity | 1 | 1994 | 11 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 1995 | 136 | 0.030 |
Why?
|
| Acyclovir | 1 | 1994 | 38 | 0.030 |
Why?
|
| Capecitabine | 1 | 2014 | 11 | 0.030 |
Why?
|
| AIDS Serodiagnosis | 1 | 1994 | 17 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2014 | 21 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 125 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2014 | 83 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1994 | 765 | 0.030 |
Why?
|
| Jaundice | 1 | 1993 | 13 | 0.030 |
Why?
|
| Risk Factors | 3 | 2015 | 5731 | 0.030 |
Why?
|
| Animals | 3 | 2020 | 20881 | 0.030 |
Why?
|
| Neoplasms | 2 | 2007 | 1667 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 567 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 365 | 0.030 |
Why?
|
| Polymers | 1 | 1994 | 244 | 0.030 |
Why?
|
| Probability | 2 | 2004 | 245 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2004 | 242 | 0.030 |
Why?
|
| Equipment Design | 2 | 2008 | 500 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2015 | 326 | 0.030 |
Why?
|
| Reference Values | 2 | 2005 | 579 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 378 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2011 | 58 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2007 | 700 | 0.020 |
Why?
|
| Epithelium | 1 | 2011 | 172 | 0.020 |
Why?
|
| Hepatic Duct, Common | 1 | 1990 | 3 | 0.020 |
Why?
|
| Prevalence | 1 | 2015 | 1619 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 1998 | 2550 | 0.020 |
Why?
|
| Microspheres | 1 | 2011 | 59 | 0.020 |
Why?
|
| Risk | 1 | 1992 | 563 | 0.020 |
Why?
|
| Sphincterotomy, Transduodenal | 1 | 1990 | 24 | 0.020 |
Why?
|
| Infarction | 1 | 1990 | 17 | 0.020 |
Why?
|
| Eclampsia | 1 | 1990 | 16 | 0.020 |
Why?
|
| Laparoscopy | 1 | 1992 | 237 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 536 | 0.020 |
Why?
|
| Necrosis | 1 | 1990 | 239 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 1992 | 419 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2015 | 756 | 0.020 |
Why?
|
| Lipids | 1 | 2011 | 298 | 0.020 |
Why?
|
| Mice | 1 | 2020 | 8474 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1054 | 0.020 |
Why?
|
| Myelin and Lymphocyte-Associated Proteolipid Proteins | 1 | 2007 | 3 | 0.020 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2007 | 12 | 0.020 |
Why?
|
| Proteolipids | 1 | 2007 | 20 | 0.020 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2007 | 14 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2007 | 27 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2007 | 17 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1990 | 705 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2007 | 132 | 0.020 |
Why?
|
| Age Factors | 2 | 2004 | 1864 | 0.020 |
Why?
|
| Vesicular Transport Proteins | 1 | 2007 | 87 | 0.020 |
Why?
|
| ROC Curve | 1 | 2007 | 392 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2007 | 199 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2007 | 248 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2008 | 281 | 0.020 |
Why?
|
| Fibrosis | 1 | 2007 | 371 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 370 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2004 | 27 | 0.010 |
Why?
|
| Thoracoscopy | 1 | 2004 | 6 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 2004 | 79 | 0.010 |
Why?
|
| Carcinoma, Large Cell | 1 | 2003 | 6 | 0.010 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2003 | 62 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2004 | 328 | 0.010 |
Why?
|
| Bile | 1 | 2002 | 35 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 498 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2004 | 319 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 714 | 0.010 |
Why?
|
| Constriction, Pathologic | 2 | 1993 | 236 | 0.010 |
Why?
|
| Time Factors | 1 | 1990 | 4655 | 0.010 |
Why?
|
| Esophagectomy | 1 | 2001 | 26 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2001 | 46 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2004 | 447 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2003 | 622 | 0.010 |
Why?
|
| Sex Factors | 1 | 2004 | 1266 | 0.010 |
Why?
|
| Leiomyoma | 1 | 2000 | 28 | 0.010 |
Why?
|
| Hospital Costs | 1 | 2000 | 117 | 0.010 |
Why?
|
| Recurrence | 1 | 2002 | 948 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 5717 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1999 | 129 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1999 | 125 | 0.010 |
Why?
|
| Congenital Abnormalities | 1 | 1999 | 42 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 442 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2000 | 504 | 0.010 |
Why?
|
| Survival Rate | 1 | 2001 | 1056 | 0.010 |
Why?
|
| Intubation, Intratracheal | 1 | 1998 | 99 | 0.010 |
Why?
|
| Rectum | 1 | 1997 | 62 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 219 | 0.010 |
Why?
|
| Swine | 1 | 1998 | 672 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 1996 | 108 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 1996 | 117 | 0.010 |
Why?
|
| Reoperation | 1 | 1996 | 467 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2001 | 1615 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 1996 | 297 | 0.010 |
Why?
|
| Cystic Duct | 1 | 1992 | 5 | 0.010 |
Why?
|
| Foreign Bodies | 1 | 1992 | 58 | 0.010 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1990 | 39 | 0.010 |
Why?
|